Tribodies are multifunctional recombinant antibody derivatives. The Fab fragment serves as a specific heterodimerization signal, and the two scFv fragments are each fused to a different Fab chain. In this way we obtain a molecule of intermediate molecular weight (100 kDa) which allows incorporating three different antibody fragments (Fig. 1). This manifold, tribody, can be used to create trivalent molecules as well as bispecific molecules with bivalent binding to only one target, as trispecific molecules. These heterodimers are stable, with each of the binders retaining their specific affinities, with the bivalent tribody having higher affinity, and higher activation of T-cell proliferation and cytotoxicity in vivo. The molecule also has more favorable properties for toxic payload delivery. It can be argued that delivering a T-cell activating activity can be regarded as a toxic function. Antibodies with such a function remaining in the body for a longer time have the potency to accumulate aspecifically or form deposits in healthy tissue.
Formats of bispecific antibodies (BsAbs)
Many formats have been developed for BsAb generation as listed in the following table.
Format | Schematic structure | Description | Example BsAb | Trademark | Company |
---|---|---|---|---|---|
tandem VHH | Tandem VHH fragment-based BsAb | N/A | |||
tandem scFv | Tandem ScFv fragment-based BsAb | AMG330 | BiTETM | Amgen | |
Dual-affinity re-targeting antibody | Tandem domain-exchanged Fv (can also be used to fuse with Fc domain to create whole Abs) | Flotetuzumab | DARTTM | Macrogenics | |
Diabody | dimer of single-chain Fv (scFv) fragment | vixtimotamab | ReSTORETM | Amphivena Therapeutics | |
(scFv)2-Fab | a Fab domain and two scFv domains bind | A-337 | ITabTM | Generon/EVIVE Biotech | |
Rat–mouse hybrid IgG | Full-size IgG-like half antibodies from two different species | Catumaxomab | TriomabTM | Trion Pharma | |
Hetero heavy chain, Common light chain | Hetero heavy chain, Common light chain | Emicizumab | ART-IgTM | Genentech/ Chugai/Roche | |
Controlled Fab arm exchange | Recombin the parental half antibodies | JNJ-64007957 | DuobodyTM | Genmab/ Janssen | |
Hetero H, forced HL IgG1 | KIH technology for heterodimerization of 2 distinct H chains, replacing the native disulfide bond in one of the CH1-CL interfaces with an engineered disulfide bond to enhance the cognate of H and L paring | MEDI5752 | DuetMabTM | MedImmune/ AstraZeneca | |
cH IgG1 | Identical heavy chains; 2 different light chains: one kappa (κ) and one lambda (λ) | NI-1701 | κλ bodyTM | Novimmune SA | |
Hetero H, CrossMab | KIH technology; domain crossover of immunoglobulin domains in the Fab region | Vanucizumab | CrossMabTM | Roche | |
scFv-Fab IgG | Fab-Fc; ScFv-Fc | Vibecotamab; M802 | XmabTM (the engineered Fc to enhance the generation of heterodimeric Fc); YBODYTM | Xencor/Amgen; YZYBio | |
VH1-VH2-CH1-Fc1(G1) x VL2-VL1-CL-Fc2(G1) | 2 binding motif in one half antibody | SAR440234 | CODV-IgTM | Sanofi | |
VL1-CL1-VH2-CH2-Fc x VH1-CH1 x VL2-CL2 | 2 binding motif in one half antibody | EMB-01 | FIT-IgTM | EPIMAB BIOTHERAPEUTICS | |
VH-1-TCR Cα x VL-1-TCR Cβ; VH-2-CH-2-Fc x VL-2-CL-2 | KIH technology; TCR Cα/Cβ is used to substitute the CH1 and CL domain in one arm | WuXibodyTM | WuXi Biologics | ||
C-terminal linker of Fc | Link the other molecules at the C-terminal of Fc | APVO442 | ADAPTIR-FLEXTM | Aptevo Therapeutics | |
Fc antigen binding site | 2 natural binding sites; 2 additional binding sites in the Fc loop | FS118 | mAb2 | F-star Therapeutics |